News of Note—Mylan now recalling 104 lots of valsartan medications


> Mylan, after initially recalling just 15 lots of valsartan-based drugs that it says were tainted by a carcinogen, has now expanded its consumer-level voluntary nationwide recall to include all 104 lots of valsartan-containing products within expiry. Release

> Boehringer Ingelheim has sold its synthetic API plant to Japan’s AGC which will now have its first FDA-approved facility in Europe in the CDMO business. Release

> After putting South Korea’s Barox on its import alert list, the FDA has issued a warning letter to the OTC repackager. Warning letter

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The FDA has issued a Form 483 to Gadea Biopharma in Leon, Spain, after an inspection of the sterile drug manufacturer lacked some of the basic processes for producing drugs. Form 483